Literature DB >> 25170213

Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer.

Yu-Long Zhang1, You-Cheng Zhang1, Wei Han1, Yu-Min Li1, Geng-Nian Wang1, Shao Yuan1, Feng-Xian Wei1, Jia-Feng Wang1, Jian-Jun Jiang1, Ya-Wu Zhang1.   

Abstract

AIM: To investigate the roles of Golgi protein (GP) 73 in the regulation of cell proliferation and apoptosis.
METHODS: Stealth RNAi targeting GP73 gene sequence was used to silence its expression in Hep G2 cells and Bel7402 cells. Stealth RNAi effects were assessed by reverse transcriptase polymerase chain reaction and ELISA. Cell proliferation assay and cell cycle analysis were assessed by MTT assay and flow cytometry. Apoptosis was assessed by flow cytometry and transmission electron microscopy. Apoptosis-related proteins were assessed by western immunoblot analysis.
RESULTS: Stealth RNAi targeting GP73 gene sequence markedly reduced the expression of GP73 gene. The reduction of GP73 in Hep G2 cells and Bel7402 cells inhibited cell proliferation and induced apoptosis, however, terminal apoptosis occurred in Hep G2 cells, but early apoptosis occurred in Bel7402 cells. Reduced expression of GP73 gene might lead to a reduction in Bcl-2/Bax ratio, an increase in cytochrome c, but a reduction in capase-3.
CONCLUSION: GP73 might play an important role in proliferation and apoptosis in hepatocellular carcinoma cells.

Entities:  

Keywords:  Apoptosis; Cell proliferation; Golgi protein-73; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25170213      PMCID: PMC4145767          DOI: 10.3748/wjg.v20.i32.11287

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma.

Authors:  Y Shi; J Chen; L Li; Z Sun; L Zen; S Xu; Y Zhang; L Zhang
Journal:  Technol Cancer Res Treat       Date:  2011-06

2.  Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption.

Authors:  Sapna Puri; Collin Bachert; Claus J Fimmel; Adam D Linstedt
Journal:  Traffic       Date:  2002-09       Impact factor: 6.215

3.  Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.

Authors:  Yilei Mao; Huayu Yang; Haifeng Xu; Xin Lu; Xinting Sang; Shunda Du; Haitao Zhao; Wang Chen; Yiyao Xu; Tianyi Chi; Zhiying Yang; Jianqiang Cai; Hui Li; Jianguo Chen; Shouxian Zhong; Smruti R Mohanti; Reynold Lopez-Soler; J Michael Millis; Jiefu Huang; Hongbing Zhang
Journal:  Gut       Date:  2010-09-28       Impact factor: 23.059

4.  Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane.

Authors:  Tomomi Kuwana; Mason R Mackey; Guy Perkins; Mark H Ellisman; Martin Latterich; Roger Schneiter; Douglas R Green; Donald D Newmeyer
Journal:  Cell       Date:  2002-11-01       Impact factor: 41.582

5.  [Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma].

Authors:  Yong-xing Bao; Ying Yang; Hua-rong Zhao; Rui Mao; Lei Xiao; Yue-feng Zhang; Tulahong Aisiker; Hao Wen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2013-07

6.  Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases.

Authors:  Liyuan Tian; Yu Wang; Dabin Xu; Junhao Gui; Xingwang Jia; Hongli Tong; Xinyu Wen; Zhennan Dong; Yaping Tian
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

7.  Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease.

Authors:  Raleigh D Kladney; Xiaoyen Cui; Gary A Bulla; Elizabeth M Brunt; Claus J Fimmel
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

8.  Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.

Authors:  Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

Review 9.  From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

Authors:  Roberta W C Pang; Ronnie T P Poon
Journal:  Oncology       Date:  2007-12-13       Impact factor: 2.935

10.  [Retrospective observation of dynamic levels of serum Golgi protein 73 in patients prior to the onset of liver cancer].

Authors:  Jian-guo Chen; Wei-zhong Lu; Yuan-rong Zhu; Yong-hui Zhang; Jian-hua Lu; Tao-yang Chen
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2013-08
View more
  9 in total

Review 1.  The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.

Authors:  Mingjie Yao; Leijie Wang; Patrick S C Leung; Yanmei Li; Shuhong Liu; Lu Wang; Xiaodong Guo; Guangde Zhou; Ying Yan; Guiwen Guan; Xiangmei Chen; Christopher L Bowlus; Tianhui Liu; Jidong Jia; M Eric Gershwin; Xiong Ma; Jingmin Zhao; Fengmin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

2.  Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF.

Authors:  Jingjing Tong; Mingjie Yao; Xiuying Mu; Leijie Wang; Xiajie Wen; Xingran Zhai; Xiang Xu; Yu Wang; Jing Chen; Xiangwei Zhai; Chongdan Guan; Fengmin Lu; Jinhua Hu
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

3.  Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility.

Authors:  Yiming Liu; Xiaodi Zhang; Ting Sun; Junchang Jiang; Ying Li; Mingliang Chen; Zhen Wei; Weiqin Jiang; Linfu Zhou
Journal:  Oncotarget       Date:  2016-04-19

Review 4.  Recent advances of GOLM1 in hepatocellular carcinoma.

Authors:  Jiuliang Yan; Binghai Zhou; Hui Li; Lei Guo; Qinghai Ye
Journal:  Hepat Oncol       Date:  2020-06-29

5.  Golgi protein 73, hepatocellular carcinoma and other types of cancers.

Authors:  Yanan Wang; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-09-25

6.  Research on Gut Microbiota-Derived Secondary Bile Acids in Cancer Progression.

Authors:  Rong Yang; Li Qian
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

7.  GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.

Authors:  Jia-Zhou Ye; Shu-Mei Yan; Chun-Ling Yuan; Hui-Ni Wu; Jin-Yan Zhang; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Yan Lin; Rong Liang
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

8.  Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.

Authors:  Nikolaos K Gatselis; Tamás Tornai; Zakera Shums; Kalliopi Zachou; Asterios Saitis; Stella Gabeta; Roger Albesa; Gary L Norman; Mária Papp; George N Dalekos
Journal:  World J Gastroenterol       Date:  2020-09-14       Impact factor: 5.742

Review 9.  Golgi protein 73 and its diagnostic value in liver diseases.

Authors:  Yanyan Xia; Yuanying Zhang; Mengjiao Shen; Hongpan Xu; Zhiyang Li; Nongyue He
Journal:  Cell Prolif       Date:  2018-10-19       Impact factor: 6.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.